Xilio Therapeutics (XLO)

• Market cap: $56.3M
• 1 day: 36.46%
• 5 days: 26.73%
• 1 month: 36.00%
• 3 months: 64.31%
• 6 months: 34.23%
• Year to date: 122.61%
• 1 year: 155.80%
• 5 years: -92.00%
• 10 years: -92.00%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Employees: 73

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 31 [Q2] → 32 (+1) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

5.39% less ownership

Funds ownership: 38.33% [Q2] → 32.94% (-5.39%) [Q3]

15% less capital invested

Capital invested by funds: $13.4M [Q2] → $11.4M (-$1.99M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 213% upside
• Avg. target: $4 213% upside
• High target: $4 213% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Dane Leone 33% 1-year accuracy 1 / 3 met price target

213% upside $4

Outperform Maintained

8 Nov 2024